Hyperfine, Inc. (HYPR) Q3 2024 Earnings Call Transcript Summary
Hyperfine, Inc. (HYPR) Q3 2024 Earnings Call Transcript Summary
Net loss for the quarter improved slightly, with a net loss of $0.14 per share compared to $0.15 per share in the same period the previous year.The following is a summary of the Hyperfine, Inc. (HYPR) Q3 2024 Earnings Call Transcript:
以下是Hyperfine, Inc.（HYPR）2024年第三季度業績會議議事錄摘要：
Financial Performance:
財務業績:
Reported a total Q3 2024 revenue of $3.6 million, up 56% year-over-year.
Achieved a gross margin of 52%, marking a record and showing continued improvement. Year-to-date gross margin also improved significantly.
Net loss for the quarter improved slightly, with a net loss of $0.14 per share compared to $0.15 per share in the same period the previous year.
Projected full-year 2024 revenue to be between $14 million to $14.5 million, with a possible gross margin of up to 50%.
報告2024年第三季度總營業收入爲360萬美元，同比增長56%。
實現52%的毛利率，創下紀錄並持續改善。年度至今毛利率也有顯著提高。
本季度淨虧損略有改善，每股淨虧損爲0.14美元，而去年同期爲0.15美元。
預計全年2024年營業收入將在1400萬至1450萬美元之間，可能的毛利率高達50%。
Business Progress:
業務進展:
Hyperfine's portable imaging systems, especially the Swoop system, continue to drive revenue with strong sales in the US and international markets.
Received FDA clearance for their ninth generation AI-powered software, improving the imaging capabilities of their ultra-low field portable brain MRI devices.
Plans to launch the next generation AI-powered software in H1 2025, aiming for significant image quality improvements.
Expansion plans include growing adoption in multiple new sites of care and broadening commercial capabilities for office settings.
Received CE approval for the ninth generation software, setting the stage for broader distribution and use in European markets.
Hyperfine的便攜式成像系統，尤其是Swoop系統，繼續帶動營業收入，在美國和國際市場實現強勁銷售。
獲得第九代人工智能軟件的FDA清除，提升其超低場便攜式腦部MRI設備的成像能力。
計劃在2025年上半年推出下一代人工智能軟件，旨在顯著提高圖像質量。
擴大計劃包括在多個新的護理場所增加採用，以及拓展辦公環境的商業能力。
獲得第九代軟件的CE批准，爲在歐洲市場更廣泛的分銷和使用鋪平道路。
Opportunities:
機會：
Expansion into new sites of care for their Swoop System, driven by technological advances and clinical evidence.
Anticipated regulatory approval in India and broadening of the European market with a strong international distribution network.
Opportunities for growth from the office setting integration, expected to contribute to growth starting in the second half of 2025.
通過技術進步和臨床證據推動Swoop系統進入新的護理場所的擴展。
預計在印度獲得監管批准，並通過強大的國際分銷網絡拓展歐洲市場。
從辦公環境整合中獲得增長機會，預計將在2025年下半年開始爲增長做出貢獻。
Risks:
風險：
The sequential and steady approach in deploying new software updates, essential for maintaining technological edge, could delay immediate realization of revenues from new capabilities.
在部署新軟件更新方面採用連續和穩定的方法，對於保持技術優勢至關重要，但可能會延遲從新能力獲得營業收入的即時實現。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
